Pluri Inc. Net Income (Loss) Available to Common Stockholders, Basic
Pluri Inc. (PLUR) reported Net Income (Loss) Available to Common Stockholders, Basic of $9.42 billion for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-09-10
- Pluri Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $411.93M, a 14.05% decline year-over-year.
- Pluri Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was $10.05B, a 53.25% increase year-over-year.
- Pluri Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $9.00B, a 62.24% increase year-over-year.
- Pluri Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was $7.99B, a 46.48% increase year-over-year.
- Pluri Inc. net income (loss) available to common stockholders, basic for fiscal 2026 was $9.42B, a 48.71% increase from fiscal 2025.
- Pluri Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was $6.33B, a 20.95% increase from fiscal 2024.
- Pluri Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was $5.24B, a 18024.91% increase from fiscal 2023.
- Pluri Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was $28.89M, a 30.18% decline from fiscal 2022.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $411.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $10.46B derived: sum of 2 quarters · filed 2026-09-10 | $19.47B derived: sum of 3 quarters · filed 2026-09-10 | $9.42B 10-K · filed 2026-09-10 |
| 2026-03-31 | $10.05B 10-Q · filed 2026-05-14 | $19.05B derived: sum of 2 quarters · filed 2026-05-14 | $9.00B 10-Q · filed 2026-05-14 | $27.52B derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | $9.00B 10-Q · filed 2026-02-12 | $8.50B 10-Q · filed 2026-02-12 | $17.47B derived: sum of 3 quarters · filed 2026-09-10 | $24.03B derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | $7.99B 10-Q · filed 2025-11-12 | $8.47B derived: sum of 2 quarters · filed 2026-09-10 | $15.03B derived: sum of 3 quarters · filed 2026-09-10 | $20.58B derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | $479.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $7.04B derived: sum of 2 quarters · filed 2026-09-10 | $12.59B derived: sum of 3 quarters · filed 2026-09-10 | $6.33B 10-K · filed 2026-09-10 |
| 2025-03-31 | $6.56B 10-Q · filed 2026-05-14 | $12.11B derived: sum of 2 quarters · filed 2026-05-14 | $5.85B 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $5.55B 10-Q · filed 2026-02-12 | $5.50B 10-Q · filed 2026-02-12 | ||
| 2024-09-30 | $5.45B 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $5.24B 10-K · filed 2025-09-17 | |||
| 2023-06-30 | $28.89M 10-K · filed 2023-09-12 | |||
| 2022-06-30 | $41.37M 10-K · filed 2023-09-12 | |||
| 2021-06-30 | $49.87M 10-K · filed 2022-09-21 | |||
| 2020-06-30 | $29.15M 10-K · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |